Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan Olender, Katherine K Perez, Alan S. Go et al.|Clinical Infectious Diseases|2020Cited by 171
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort studyBelén Gutiérrez‐Gutiérrez, Chiara Fanciulli, Alberto M. Borobia et al.|The Lancet Infectious Diseases|2021Cited by 104
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, M. A. von Wichmann, Esteban Ribera et al.|Clinical Infectious Diseases|2017Cited by 103
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013Paz Sobrino‐Vegas, Almudena García Torre, Santiago Moreno et al.|Journal of Infection|2016Cited by 89
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M. Gatell, Nadine Ktorza, Lambert Assoumou et al.|Clinical Infectious Diseases|2018Cited by 48